Chengdu Kanghong Biotech Co., Ltd.

Quick facts

Phase 3 pipeline

• conbercept, Fixed · Ophthalmology
  Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.
• Conbercept ophthalmic injection · Ophthalmology
  Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
• conbercept, PRN · Ophthalmology
  Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).
• Placebo + Paclitaxel · Oncology
  Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and dividing.

Phase 2 pipeline

• Intravitreal injection of KH902 · Ophthalmology
  KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

Phase 1 pipeline

• KH902

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chengdu Kanghong Biotech Co., Ltd. portfolio CI brief
• Chengdu Kanghong Biotech Co., Ltd. pipeline updates RSS